People
Derek Meilman focusses on complex international mergers, acquisitions and strategic joint ventures, often in emerging markets. He has experience across a wide range of industries, with a particular emphasis on the consumer retail and industrial sectors. His clients include major multinational companies, private equity groups, governments (including sovereign wealth funds and multilateral organizations) and family offices. Derek has a BA from Brown University and a JD from the Duke University School of Law. He is qualified as an attorney in New York State and as a solicitor in England & Wales and the Republic of Ireland. Derek serves as a non-executive director on the board of CA Ron Santa Teresa, the Caracas stock exchange-listed producer of the award-winning ‘Santa Teresa 1796’ solera method rum.
J.D., Duke University School of Law
B.A., Brown University
England and Wales
Ireland
New York
French
Italian
Spanish
Turkish
December 2, 2021
BOA Acquisition Corp. to Merge with Selina in de-SPAC Transaction
December 2, 2021
K&S advises BOA Acquisition on its $1.2B acquisition of Selina
August 24, 2021
Arbor Pharmaceuticals to Merge with Azurity Pharmaceuticals
Represented Afendis Capital Partners as transaction sponsor in connection with the acquisition by a private equity consortium, including Afendis and Metric Capital Partners, of a 30% stake in Turkish generic drug maker Sanovel.
Represented Olivier Creed in the sale of Creed fragrances, one of the world’s leading luxury perfume houses, to BlackRock Long Term Private Capital, a perpetual capital private equity fund within the world’s largest asset manager, and Javier Ferrán, Chairman of Diageo.
Represented Ron Santa Teresa of Venezuela in connection with an international distribution alliance with Bacardi, the world's largest privately owned spirits company
See more
March 11, 2021
Biden Administration - What's Ahead for the Life Sciences Industry?
December 2, 2021
BOA Acquisition Corp. to Merge with Selina in de-SPAC Transaction
December 2, 2021
K&S advises BOA Acquisition on its $1.2B acquisition of Selina
August 24, 2021
Arbor Pharmaceuticals to Merge with Azurity Pharmaceuticals
Represented Afendis Capital Partners as transaction sponsor in connection with the acquisition by a private equity consortium, including Afendis and Metric Capital Partners, of a 30% stake in Turkish generic drug maker Sanovel.
Represented Olivier Creed in the sale of Creed fragrances, one of the world’s leading luxury perfume houses, to BlackRock Long Term Private Capital, a perpetual capital private equity fund within the world’s largest asset manager, and Javier Ferrán, Chairman of Diageo.
Represented Ron Santa Teresa of Venezuela in connection with an international distribution alliance with Bacardi, the world's largest privately owned spirits company
See more
March 11, 2021
Biden Administration - What's Ahead for the Life Sciences Industry?
December 2, 2021
BOA Acquisition Corp. to Merge with Selina in de-SPAC Transaction
December 2, 2021
K&S advises BOA Acquisition on its $1.2B acquisition of Selina
August 24, 2021
Arbor Pharmaceuticals to Merge with Azurity Pharmaceuticals
J.D., Duke University School of Law
B.A., Brown University
England and Wales
Ireland
New York
French
Italian
Spanish
Turkish